A Phase Ib Study of Rezatapopt in Combination With Azacitidine in Patients With TP53Y220C Mutant Myeloid Malignancies (Acute Myeloid Leukemia or Myelodysplastic Syndrome)

NCT06616636 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

24

Enrollment

OTHER

Sponsor class

Conditions

Myelodysplastic Syndrome
Acute Myeloid Leukemia

Interventions

DRUG: Azacitidine
DRUG: Rezatapopt

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]
[object Object]